pSivida appointment expected to inject US experience
04 April, 2002 by Melissa TrudingerAustralian company pSivida announced today that it has appointed Hal Kruth to the board of pSivida's UK subsidiary pSiMedica.
Primate breeding/testing facility to be built
04 April, 2002 by Tanya HollisMelbourne primate researchers could look to the United States for further funding to back a new Gippsland monkey house.
EU approves Compumedics sleep system
03 April, 2002 by Tanya HollisA European window of opportunity has opened for sleep disorders device developer Compumedics, with the news it has gained EU approval to market its Somte system.
Prima US subsidiaries score patent wins
03 April, 2002 by Melissa TrudingerUS patents have been granted to Arthron and Cancer Vac, subsidiary companies of Australian company Prima BioMed.
Alchemia teams with Belgian screening company
03 April, 2002 by Melissa TrudingerAustralian company Alchemia has begun a drug discovery collaboration with Belgium's Euroscreen.
New blow for Amrad as collaborators pull out
03 April, 2002 by Tanya HollisTwo early-stage research projects will revert back to the Amrad Corporation (ASX: AML) fold after collaborators decided they no longer wished to pursue them.
Takara spins off biotech unit
02 April, 2002 by Martyn WilliamsJapanese liquor maker Takara Shuzo has stepped up its push to make a name for itself in the biotechnology sector by separating its bio-related activities into a new company.
Cochlear hearing aid approved
02 April, 2002 by Daniella GoldbergListening device maker Cochlear has received approval from the Therapeutic Goods Administration (TGA) for sale of its ESPrit 3G in Australia, after gaining approval to sell in the US market last week.
Progen, Griffith team up in heparanase project
28 March, 2002 by Pete YoungQueensland private sector and academic researchers will share an Australian Research Council grant to probe an enyzme that plays a role in cancer and inflammatory diseases.
VC urges more pharma biotech commitment
28 March, 2002 by Pete YoungThe time is ripe to insist multinational pharmaceuticals lift their commitment to the local life sciences industry, claims venture capitalist Dr Geoff Brooke.
Cloned calves a first for Australia
27 March, 2002 by Melissa TrudingerIn a first for the Australian dairy industry, four genetically modified calves have been born with an additional protein gene for milk protein production.
Metabolic in trans-Tasman licensing, research deal
27 March, 2002 by Tanya HollisMetabolic Pharmaceuticals has announced a trans-Tasman licensing deal and research collaboration to develop a new osteoporosis treatment.
Xenome in third screening partnership
27 March, 2002 by Pete YoungBrisbane biotech and animal venom specialist Xenome Ltd has found yet another partner to screen its library of bioactive peptide molecules.
Victorian plant genetics company launched
26 March, 2002 by Tanya HollisMost of Australia's staple foods would be altered through genetic technologies within the next 20 years, according to one of the nation's most celebrated scientists.
Cyclotide research looks for new drugs
26 March, 2002 by Melissa TrudingerCyclotides are a unique group of plant proteins with unusual properties. Kalthera, a small Queensland biotech company, is developing technology to use them in therapeutic applications.
